Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
Condition: Leukemia
MeSH terms: Leukemia
Intervention: aldesleukin; filgrastim; busulfan; cytarabine; etoposide; idarubicin; autologous hematopoietic stem cell transplantation; bone marrow transplantation; peripheral blood stem cell transplantation; total-body irradiation
Intervention MeSH terms: Cytarabine; Aldesleukin; Etoposide; Idarubicin; Busulfan
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 60.0
Sex: All
Minimum age: 16 Years
Maximum age: 60 Years
Healthy volunteers: No
Keywords: adult acute myeloid leukemia in remission; adult acute myeloid leukemia with 11q23 (MLL) abnormalities; adult acute myeloid leukemia with inv(16)(p13;q22); adult acute myeloid leukemia with t(16;16)(p13;q22); adult acute myeloid leukemia with t(8;21)(q22;q22); adult acute basophilic leukemia; adult acute eosinophilic leukemia; adult erythroleukemia (M6a); adult pure erythroid leukemia (M6b); adult acute megakaryoblastic leukemia (M7); adult acute minimally differentiated myeloid leukemia (M0); adult acute monoblastic leukemia (M5a); adult acute monocytic leukemia (M5b); adult acute myeloblastic leukemia with maturation (M2); adult acute myeloblastic leukemia without maturation (M1); adult acute myelomonocytic leukemia (M4)

Summary:

      RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of
      cancer cells by stopping them from dividing or killing them. After treatment, stem cells are
      collected from the patient's blood and/or bone marrow and stored. More chemotherapy and
      radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem
      cells are then returned to the patient to replace the blood-forming cells that were destroyed
      by the chemotherapy and radiation therapy. Giving aldesleukin after transplant may help keep
      cancer cells from coming back after transplant.

      PURPOSE: This phase II trial is studying the side effects and how well giving busulfan and
      etoposide together with total-body irradiation followed by autologous stem cell transplant
      and aldesleukin works in treating patients with acute myeloid leukemia in first remission.
    

Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute myeloid leukemia (AML)

               -  FAB types M0-2 and M4-M7

                    -  No M3 disease

          -  In first complete hematological remission as confirmed by marrow aspiration and biopsy

               -  No cytogenetic abnormality in the remission marrow

               -  In complete remission for less than 6 months

                    -  Patients who have been in complete remission for more than 6 months may be
                       eligible upon approval of the principal investigator

          -  No prior myeloproliferative disorder (e.g., chronic myeloid leukemia, myelofibrosis,
             essential thrombocytosis, or polycythemia vera)

          -  No prior myelodysplasia or secondary leukemia

        PATIENT CHARACTERISTICS:

          -  FEV_1 > 60%

          -  DLCO > 50%

          -  Cardiac ejection fraction ≥ 50%

          -  Creatinine clearance > 60 mL/min

          -  No severe chronic medical or psychological illness that, in the judgement of the
             principal investigator, would jeopardize the ability of the patient to tolerate
             aggressive chemotherapy

          -  No HIV positivity

          -  Not pregnant

          -  Negative pregnancy test

        PRIOR CONCURRENT THERAPY:

          -  Prior consolidation therapy allowed

          -  No concurrent use the following medications during aldesleukin therapy :

               -  Corticosteroids (including blood product "pre-meds")

               -  Pentoxifylline

               -  IV or intrathecal methotrexate

               -  IV immunoglobulin

               -  Other cytokines or growth factors